Physician profile
Jay Kwok
NPI 1275783607
$14,119.52
in general payments reported to CMS, 2019-2025
25 companies · $2,566 in 2025
The $2,566 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,533 · 2020: $954 · 2021: $2,612 · 2022: $2,662 · 2023: $1,667 · 2024: $2,125 · 2025: $2,566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,358.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $1,901.51 | 2020-2025 | Acthar |
| Abbvie INC. | $1,479.93 | 2022-2025 | |
| Alcon Vision LLC | $1,310.52 | 2019-2025 | Rocklatan, Tryptyr, Eysuvis |
| Dompe US, INC. | $1,253.50 | 2021-2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $1,031.12 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,028.63 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $889.50 | 2024-2025 | Xdemvy |
| Allergan, INC. | $792.11 | 2020-2022 | |
| Bausch & Lomb Americas INC. | $666.48 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Sun Pharmaceutical Industries INC. | $503.92 | 2019-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $487.51 | 2019-2023 | |
| Johnson & Johnson Vision Care, INC. | $467.15 | 2019-2023 | Acuvue |
| Amgen INC. | $335.14 | 2024-2025 | Tepezza |
| Kala Pharmaceuticals, INC. | $332.68 | 2021-2022 | |
| Horizon Therapeutics Plc | $310.94 | 2022-2023 | Tepezza |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $264.09 | 2022-2024 | Tyrvaya, Ryzumvi |
| Thea Pharma INC. | $256.45 | 2022-2025 | Iyuzeh |
| Shire North American Group INC | $252.09 | 2019 | |
| Harrow Eye, LLC | $156.29 | 2024-2025 | Vevye |
| Apellis Pharmaceuticals, INC. | $120.39 | 2024 | Syfovre |
| Alcon Research LLC | $94.44 | 2019 | |
| Rxsight INC | $81.22 | 2022-2024 | Light Adjustable Lens (Lal), Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Visionix USA, INC | $41.67 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $40.48 | 2019-2022 | |
| Glaukos Corporation | $21.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Kwok listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.